Lv1
20 积分 2024-08-07 加入
分子检测联合类器官药敏试验优化获得性EGFR T790M突变非小细胞肺癌奥希替尼耐药后治疗方案的研究
21天前
已完结
EGFR突变合并MET扩增非小细胞肺癌免疫分子特征与免疫治疗疗效的相关性
3个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
5个月前
已完结
Advancements in small cell lung cancer
5个月前
已完结
Advancements in small cell lung cancer
5个月前
已完结
circ＿EPHB4协同YTHDF3通过N6-甲基腺苷依赖性稳定Wnt3促进胶质瘤进展
5个月前
已完结
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
7个月前
已完结
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
9个月前
已完结
Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study
11个月前
已完结
皖公网安备34019202002308
